All > Non Small Cell Lung Cancer

Atezolizumab for Non-Small Cell Lung Cancer

University Cancer and Blood Center, Athens, GA
Non-Small Cell Lung Cancer+1 More ConditionsAtezolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the effectiveness of a new cancer treatment in people with squamous or non-squamous non-small cell lung cancer who haven't received prior systemic therapy. Up to 83 people will be enrolled in the study.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
Brigatinib
1
Atezolizumab
1
VB10.NEO

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: approximately 2 years

approximately 2 years
Disease Control Rate (DCR)
Duration of response (DoR)
Objective Response Rate (ORR)
Overall survival (OS)
Progression Free Survival (PFS)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Brigatinib
1
Atezolizumab
1
VB10.NEO

Side Effects for

Atezolizumab
27%Fatigue
25%Decreased appetite
24%Cough
19%Dyspnoea
19%Asthenia
18%Constipation
18%Nausea
18%Pyrexia
16%Diarrhoea
13%Arthralgia
12%Anaemia
12%Vomiting
11%Rash
11%Back pain
11%Musculoskeletal pain
10%Headache
9%Oedema peripheral
9%Weight decreased
9%Insomnia
9%Chest pain
9%Pruritus
9%Pain in extremity
8%Dizziness
7%Myalgia
7%Upper respiratory tract infection
7%Aspartate aminotransferase increased
7%Haemoptysis
6%Nasopharyngitis
6%Influenza like illness
6%Alanine aminotransferase increased
6%Bronchitis
6%Productive cough
5%Depression
5%Dry skin
5%Musculoskeletal chest pain
4%Abdominal pain
4%Urinary tract infection
4%Paraesthesia
4%Neuropathy peripheral
3%Pneumonia
3%Stomatitis
3%Dysgeusia
2%Pleural effusion
2%Neutropenia
2%Malaise
1%Sepsis
1%Respiratory tract infection
1%Peripheral sensory neuropathy
1%Lacrimation increased
1%Pneumonitis
1%Pulmonary embolism
1%Alopecia
1%Mucosal inflammation
1%Bone pain
This histogram enumerates side effects from a completed 2019 Phase 3 trial (NCT02008227) in the Atezolizumab ARM group. Side effects include: Fatigue with 27%, Decreased appetite with 25%, Cough with 24%, Dyspnoea with 19%, Asthenia with 19%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

NT-I7 and atezolizumab
1 of 1

Experimental Treatment

83 Total Participants · 1 Treatment Group

Primary Treatment: Atezolizumab · No Placebo Group · Phase 2

NT-I7 and atezolizumabExperimental Group · 2 Interventions: efineptakin alfa, Atezolizumab · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 2 years

Who is running the clinical trial?

NeoImmuneTechLead Sponsor
8 Previous Clinical Trials
488 Total Patients Enrolled
Roche Pharma AGIndustry Sponsor
393 Previous Clinical Trials
359,983 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your organs and blood work must be functioning properly.
References

Frequently Asked Questions

Are any new participants being taken into this experiment?

"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical study, which was first posted on November 3rd 2021, is actively recruiting. Roughly 83 patients need to be recruiter from 14 different medical centres." - Anonymous Online Contributor

Unverified Answer

Has Atezolizumab been granted regulatory approval by the FDA?

"The safety of Atezolizumab has been rated 2 on our internal scale, as this Phase 2 trial suggests some level of security with no clinical evidence for its effectiveness." - Anonymous Online Contributor

Unverified Answer

How many sites are participating in the execution of this clinical research?

"Patients interested in participating can find the trial at Norton Cancer Institute (Louisville, KY), BRCR Medical Center (Plantation, FL) and Innovative Clinical Research Institute (Whittier, CA) as well as 14 other locations." - Anonymous Online Contributor

Unverified Answer

In what illnesses is Atezolizumab commonly employed?

"Atezolizumab is a popular treatment for small cell lung cancer, but it can also be utilized to combat postoperative malignancies and non-small cell lung carcinoma." - Anonymous Online Contributor

Unverified Answer

What other explorations of Atezolizumab have been conducted?

"Atezolizumab was initially studied in 2008 by SCRI Tennessee Oncology Chattanooga. Since then, a total of 80 trials have concluded and there are currently 360 active studies being conducted mostly out of Louisville, Kentucky." - Anonymous Online Contributor

Unverified Answer

How many volunteers are participating in this research endeavor?

"NeoImmuneTech requires a total of 83 eligible individuals to successfully run this trial. Those interested can be seen at the Norton Cancer Institute in Louisville, Kentucky or BRCR Medical Center located in Plantation, Florida." - Anonymous Online Contributor

Unverified Answer

Is this the inaugural implementation of this medical experiment?

"Atezolizumab has been under scrutiny since 2008, when Hoffmann-La Roche sponsored its first clinical trial. This Phase 2 drug was approved after the original study of 720 patients and is now being investigated in 360 trials across 74 countries and 1646 cities." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top